Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report links sorafenib treatment in a 22-year-old man with relapsed acute myeloid leukemia to a rare instance of drug-induced pityriasis rubra pilaris-like eruption.

This study concluded that leucocyte-rich PRP has a continuous stimulatory effect on human fibroblast cells, enhancing their proliferation, migration, and impacting gene expression of the extracellular matrix and adhesion molecules.

In this study, the researchers reported that the safety profile was similar across all DMARD treatment regimens for early rheumatoid arthritis, but the most severe side effects occurred in the leflunomide group.

This case report by the researchers observed a complete remission of lichen planopilaris in a 58-year-old woman after treatment with the JAK-1 inhibitor abrocitinib, although they noted that concurrent topical therapy might have contributed to this outcome.

This study found that vinblastine treatment rapidly increased platelet counts in childhood refractory immune thrombocytopenia, providing effective control of bleeding symptoms, although side effects like neuropathic pain were common and resolved with dose adjustments.

This review discusses the potential applications of injectable platelet‐rich fibrin in various conditions and reports no new clinical results; the authors highlight its favorable use in comparison to existing treatments.

This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.

The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

This study found that among anti-TNF-α agents, certolizumab is the least likely to cause paradoxical reactions such as psoriatic alopecia and appears to be an effective and safe option for managing psoriasis and PsA while minimizing these risks.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

This case report of an infant with IPEX syndrome highlights the importance of early recognition and treatment, as the patient experienced severe symptoms and succumbed before stem cell transplantation.

This review discusses the mechanisms associated with protoporphyrin IX in living cells and reports no clinical results; the authors emphasize its potential in cancer diagnosis and the risks of toxicity.

In this case study, a patient with moderate papulopustular acne showed improvement in acne scars and active lesions after three monthly treatments with autologous plasma-rich growth factors, which help regulate inflammation, inhibit bacterial growth, and restore collagen.

This study found that the PVP protocol, combining Peptichemio, vincristine, and 6-methylprednisolone, resulted in remission for diffuse non-Hodgkin's lymphomas with moderate side effects.

This study showed that intralesional injections of pentoxifylline may be an effective and safe alternative to triamcinolone acetonide for treating localized alopecia areata.

This study suggests that combining tranexamic acid with low-dose oral retinoids may offer moderate to good improvements for lichen plan pigmentosus, although larger trials are needed for confirmation.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This study found that clinicians treating alopecia areata prioritize JAK inhibitor treatments with higher efficacy and faster initial hair growth, regardless of dosing frequency, and preferred the treatment option with ritlecitinib 50-mg data the least among several blinded profiles.

Martin-Perez et al. show that rapamycin's beneficial effects in a mouse model of Leigh syndrome are linked to the downregulation of protein kinase C.

This case report describes two patients experiencing a bortezomib-induced skin eruption as multiple plaques on the trunk, with the lesions resolving spontaneously in about a week.

This abstract reports preliminary data on the antidepressant reboxetine, noted for its different mode of action, discussed at a major psychiatry conference; it provides no new research findings.

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

This study found that while Platelet Rich Plasma injections led to some clinical and immunological improvements in psoriatic plaques, it could not be recommended as a standalone treatment for localized plaque psoriasis.

This study developed a legally valid, evidence-based informed consent document specifically for platelet-rich plasma injections, intended to enhance patient rights and communication, and support legal defense in malpractice cases.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

This article reviews systemic lupus erythematosus (SLE) and highlights the FDA approval of belimumab, marking the first new SLE treatment in nearly 50 years, but reports no new clinical trial results.

This study found that the aromatic retinoic acid derivative Ro 10-9359 provided excellent results in 64% of severe psoriasis patients, especially in those with erythrodermic and pustular types, though relapses and side effects were noted.